The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical benefits of GLP-1 receptor agonists have been extended to heart failure, with improvements in 6-minute walk distance and quality of life, and a lower rate of hospitalization for heart failure in patients with obesity-associated heart failure with preserved ejection fraction.
“These clinical benefits have been extended to the setting of heart failure (HF), with improvements in 6-minute walk distance and quality of life, and a lower rate of hospitalization for HF in patients with obesity-associated HF with preserved ejection fraction (HFpEF).[6][7][8]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [7]
The Results report benefits for 6-minute walk distance and KCCQ quality-of-life scores, and the Discussion describes improved exercise function in participants with obesity-related HFpEF and type 2 diabetes (page numbers unavailable). The paper does not establish a lower rate of heart-failure hospitalization; its Discussion says the trial collected few hospitalizations and urgent visits. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Sparse data bias: a problem hiding in plain sight
Greenland, S., Mansournia, M. A., & Altman, D. G. (2016) · BMJ · doi:10.1136/bmj.i1981 · Cited by 898
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationButler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Self-citationBorlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02526-x · Cited by 215
Self-citationKosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.05.010 · Cited by 97
Self-citationAguilar, D., Deswal, A., Ramasubbu, K., Mann, D. L., & Bozkurt, B. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.041 · Cited by 96
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.022 · Cited by 95
Self-citation
Flagged first, then by citations
Research works printed but not linked: 13
- Kapelios, 2023, Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction, Card Fail Rev, 9, e14, 10.15420/cfr.2023.03 · DOI
- Shah, 2020, Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure, Nat Commun, 11, 163, 10.1038/s41467-019-13690-5 · DOI
- Kitzman, 2018, Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF, JACC Heart Fail, 6, 1008, 10.1016/j.jchf.2018.08.007 · DOI · Paper page
- Jackson, 2022, Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction, Eur J Heart Fail, 24, 497, 10.1002/ejhf.2403 · DOI
- Abudureyimu, 2022, Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics, J Mol Cell Biol, 14, 10.1093/jmcb/mjac028 · DOI
- Green, 2000, Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure, J Am Coll Cardiol, 35, 1245, 10.1016/S0735-1097(00)00531-3 · DOI · Paper page
- Spertus, 2020, Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review, J Am Coll Cardiol, 76, 2379, 10.1016/j.jacc.2020.09.542 · DOI · Paper page
- Aalen, 1978, An empirical transition matrix for non-homogeneous Markov chains based on censored observations, Scand J Stat, 5, 141
- Brands, 2012, Sodium-retaining effect of insulin in diabetes, Am J Physiol Regul Integr Comp Physiol, 303, R1101, 10.1152/ajpregu.00390.2012 · DOI
- Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
- Davies, 2021, Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, Lancet, 397, 971, 10.1016/S0140-6736(21)00213-0 · DOI · Paper page
- Shah, 2024, Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials, Eur Heart J, 45, 3254, 10.1093/eurheartj/ehae322 · DOI · Paper page
- Hernán, 2010, The hazards of hazard ratios, Epidemiology, 21, 13, 10.1097/EDE.0b013e3181c1ea43 · DOI
Cited by
Sorted by citations
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Metadata
- Authors
- Davies, M. J., van der Meer, P., Verma, S., Patel, S., Chinnakondepalli, K. M., Borlaug, B. A., Butler, J., Kitzman, D. W., Shah, S. J., Harring, S., Salsali, A., Rasmussen, S., von Lewinski, D., Abhayaratna, W., Petrie, M. C., & Kosiborod, M. N.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2025-03
- Volume
- 13
- Issue
- 3
- Pages
- 196-209
- ISSN
- 2213-8587
- Cited by
- 32
- References
- 11
- Language
- en
- Licence
- Funders
- Novo Nordisk A/S
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
